Table 2.
Dose Conversion from Oral Risperidone to Subcutaneously Administered Long-Acting Risperidone
| Risperidone (Oral Formulation) | Risperidone (SQ Formulation) |
|---|---|
| 4 mg/d | 120 mg monthly |
| 3 mg/d | 90 mg monthly |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.